News
Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...
Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...
GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...
Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results